Fuan Pharmaceutical issued a profit warning, expecting a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of the year, a year-on-year decrease of 39.95% to 53.81%

Fuan Pharmaceutical expects a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of 2025, a year-on-year decrease of 39.95% to 53.81%. The net profit after deducting non-recurring gains and losses is expected to be 91 million to 121 million yuan, a year-on-year decrease of 40.50% to 55.25%. The company stated that the implementation of centralized procurement policies has led to a significant decline in the sales prices of major products, resulting in reduced operating income and pressure on profit margins